Market Place
Sourcing Support
Menarini Group Presents ORSERDU® Data at SABCS 2024
26 Nov 2024 //
PR NEWSWIRE
Menarini Presents Expanded ORSERDU® Data at SABCS for ER+, HER2- mBC
25 Nov 2024 //
BUSINESSWIRE
Menarini Elacestrant Mbc Combos: Electra Elevate Updates Asco 2024
23 May 2024 //
BUSINESSWIRE
LaVoieHealthScience Wins PRWeek Launch Campaign Award
22 May 2024 //
BUSINESSWIRE
Menarini Presented Efficacy Data from Phase 1b/2 Combination Studies of ORSERDU
11 Dec 2023 //
PR NEWSWIRE
Menarini Presents Progression-Free Survival Data from EMERALD Clinical Study
08 Dec 2023 //
BUSINESSWIRE
Menarini Group Announces New Data on ORSERDU® (elacestrant) at Symposium
21 Nov 2023 //
PR NEWSWIRE
Menarini Group Announces New Data on ORSERDU
20 Nov 2023 //
BUSINESSWIRE
Menarini and SciClone Pharma Announce Exclusive Sub-Licensing Collaboration
07 Nov 2023 //
BUSINESSWIRE
Carrick Announces First Patient Dosed in Phase 2 Trial of Samuraciclib
18 Oct 2023 //
GLOBENEWSWIRE
Stemline Therapeutics` Orserdu (elacestrant) Receives Approval in Europe
09 Oct 2023 //
EMA
Menarini`s Orserdu granted EU nod for advanced breast cancer
21 Sep 2023 //
BUSINESSWIRE
European Commission Approves Menarini Group’s ORSERDU® (Elacestrant)
20 Sep 2023 //
BUSINESSWIRE
ECA Elacestrant for Pretreated, ESR1+, ER+/HER2– Breast Cancer
20 Sep 2023 //
ONCLIVE
Menarini Receives Positive CHMP Opinion Recommending EC Approval of ORSERDU
21 Jul 2023 //
BUSINESSWIRE
Early signals suggest oral SERD’s potential for more breast cancer patients
30 May 2023 //
PHARMACEUTICAL TECHNOLOGY
Menarini Shares Analysis from EMERALD Clinical Study of ORSERDU
26 May 2023 //
PR NEWSWIRE
Menarini Group Shares New Analysis from EMERALD Clinical Study of ORSERDU®
26 May 2023 //
PR NEWSWIRE
ORSERDU Now Available from Onco360 for the Treatment of Postmenopausal Women
02 Feb 2023 //
BUSINESSWIRE
Menarini gains first FDA approval for oral SERD in breast cancer
31 Jan 2023 //
FIERCE PHARMA
Carrick Therapeutics and Menarini to evaluate breast cancer combo therapy
20 Dec 2022 //
CLINICALTRIALSARENA
Carrick Therapeutics and Menarini to evaluate breast cancer combo therapy
20 Dec 2022 //
CLINICALTRIALSARENA
Menarini Presents Updated Results from Pivotal Ph3 EMERALD Trial at the 2022
30 Nov 2022 //
BUSINESSWIRE
Menarini`s Elacestrant MAA Accepted for Review by EMA
19 Aug 2022 //
BUSINESSWIRE
Menarini Group`s Elacestrant MAA Accepted for Review by EMA for Breast Cancer
19 Aug 2022 //
PRNEWSWIRE
Menarini`s filing for oral SERD elacestrant gets FDA priority review
12 Aug 2022 //
BUSINESSWIRE
Menarini Group’s Elacestrant Granted Priority Review by the U.S. FDA
11 Aug 2022 //
BUSINESSWIRE
Menarini Group and Radius Health Submit NDA to the U.S. FDA for Elacestrant
22 Jun 2022 //
PRNEWSWIRE
Menarini, Radius Health present analysis from elacestrant PIII trial at 2022
06 Jun 2022 //
PRNEWSWIRE
Menarini, chased by 3 Big Pharmas, records breast cancer win
22 Oct 2021 //
FIERCEBIOTECH
Radius rockets higher as Kelly Martin boasts of a big PhIII success
21 Oct 2021 //
YAHOOFINANCE
Radius Health & Menarini-Gruppe liefern Elacestrant Update
27 Sep 2020 //
PRNEWSWIRE
Radius Health & Menarini Group Provide Elacestrant Update
25 Sep 2020 //
PRNEWSWIRE
Radius Health & Menarini Group Provide Elacestrant Update
24 Sep 2020 //
PRNEWSWIRE
